title: Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra).
abstract: OBJECTIVE
  We have analyzed retrospectively the evolution of metabolic parameters in a cohort of 159 HIV-infected patients taking a lopinavir/ritonavir-containing regimen during a mean period of 15 months.
  
  
  METHODS
  This study was completed by an additional evaluation after strict 12 hours fasting of total cholesterol (TC), HDL-c, LDL-c, triglycerides (TG), glucose, and insulin levels in a subset of 100 patients from the cohort.
  
  
  RESULTS
  TC and TG levels increased early after introduction of lopinavir/ritonavir, but remained subsequently stable. After a median of 15 months, TC was greater than normal laboratory range in 46% of cases and TG levels were greater than normal laboratory range in 52% of cases. However, in nearly 90% of these cases, elevations were less than or equal to grade 2. These increases were dependant on CDC stage and lipid levels at lopinavir/ritonavir initiation. No impact on glucose metabolism was found.
  
  
  CONCLUSIONS
  These results are particularly reassuring for the use of lopinavir/ritonavir in everyday practice.
authors.affiliation: Department of Infectious Diseases, Chalucet Hospital, Toulon, France. avps@club-internet.fr
authors.forename: Alain
authors.initials: A
authors.lastname: Lafeuillade
authors.forename: Gilles
authors.initials: G
authors.lastname: Hittinger
authors.forename: Gisèle
authors.initials: G
authors.lastname: Philip
authors.forename: Véronique
authors.initials: V
authors.lastname: Lambry
authors.forename: Patricia
authors.initials: P
authors.lastname: Jolly
authors.forename: Cécile
authors.initials: C
authors.lastname: Poggi
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D015331:Cohort Studies; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology*; D007328:Insulin / Q000097:blood; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D008076:Cholesterol, HDL; D017320:HIV Protease Inhibitors; D007328:Insulin; D011744:Pyrimidinones; D014280:Triglycerides; D061466:Lopinavir; D002784:Cholesterol; D019438:Ritonavir